Email this article Comparative efficacy of combined treatment with intron A and pegintron in combination with ribavirin in patients with chronic hepatitis С
- Authors: Gromova NI1, Bogomolov BP1
-
Affiliations:
- Issue: Vol 79, No 2 (2004)
- Pages: 31-35
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29752
- ID: 29752
Cite item
Full Text
Abstract
Aim. To investigate the efficacy of combined therapy of patients with chronic hepatitis С (СНС) including intron A, pegintron (preparations of alpha-2b interferon) and ribavirin, and evaluation of the above treatment side effects.
Material and methods. 47 СП С patients (38 males and 9 females) were divided into two groups. 22 patients of group 1 received intron A and ribavirin, 25 patients of group 2 were given pegintron and ribavirin for 6-12 months. The examination made before the treatment, during the treatment and after it included clinical, biochemical, virusological blood tests, tests for autoantibodies, thyroid hormones, ultrasound investigation.
Results. The response in group 1 was 55%, in group 2 - 72.7%. In group 2, CNS and skin side effects occurred more frequently. After the treatment side effects regressed in 95.8% patients. Conclusion. The pilot experience in Russia confirmed the findings of the foreign investigators on higher efficacy of combined treatment with pegilized interferons (pegintron) and ribavirin vs combination of intron A with ribavirin. It is shown that side effects of the above treatment can be corrected in outpatient medication.
Material and methods. 47 СП С patients (38 males and 9 females) were divided into two groups. 22 patients of group 1 received intron A and ribavirin, 25 patients of group 2 were given pegintron and ribavirin for 6-12 months. The examination made before the treatment, during the treatment and after it included clinical, biochemical, virusological blood tests, tests for autoantibodies, thyroid hormones, ultrasound investigation.
Results. The response in group 1 was 55%, in group 2 - 72.7%. In group 2, CNS and skin side effects occurred more frequently. After the treatment side effects regressed in 95.8% patients. Conclusion. The pilot experience in Russia confirmed the findings of the foreign investigators on higher efficacy of combined treatment with pegilized interferons (pegintron) and ribavirin vs combination of intron A with ribavirin. It is shown that side effects of the above treatment can be corrected in outpatient medication.
References
- Manns М. P., McHutchison J. G., Gordon S. С. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358 (9286): 958-965.
- Блохина Н. Л. Современные представления о комбинированной терапии больных ХГС. Вирус, гепатиты. Достижения и перспект. 2000; 2 (9): 6-9.
- Боек А. Д. Актуальные вопросы лечения больных ХГС. Мир вирус, гепатитов. 2000; 10: 5-6.
- Лопаткииа Т. Н. Современная комбинированная терапия , хронического гепатита С пегинтроном и ребетолом (обзор : литературы). Вир. Гепатиты. Достижения и перспект. 2001; 3 (13): 8-11.
- Крель П. Е. Современные представления о терапии вирусных гепатитов. В кн.: Материалы научно-практического семинара. Этиология, клиника и лечение вирусных гепатитов. 4 окт. 2001 г. М.; 2001. 27-41.
- Богомолов Б. П., Васильева Т. В., Девяткин А. В., Паршина Р. Г. Лечение интроном А вирусных гепатитов различных типов. В кн.: Тезисы докладов V Всероссийского съезда инфекционистов. М.; 1998.
- Волкова М. А. Интерфероны и их противовирусное действие. Вирус, гепатиты. Достижения и перспект. 1999; 2 (6): 3-11.
- Змызгова А. В. Интерферонотерапия вирусных гепатитов. М.; 1999.
- Poynard Т., Marcellin P., Lee S. et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus for treatment of chronic infection with HCV. Lancet 1998; 352: 1426-1432.
- Mangi A., Villani M. R. Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis С Hepatology 2001; 33 (4): 989-993.
- Никитин И. Г., Сторожаков Г. И. Пегилированные лекарственные препараты: современное состояние проблемы и перспективы (обзор литературы). Вирус, гепатиты. Достижения и перспект. 2001; 3 (13): 3-8.
- Bruce A. Clinical considerations in pegylated protein therapy. From Res. To Pract. 2001; 3 (1): 3-9.
- Glue P., Fang J., Rouzier-Panis R. PEG-interferon-alfa 2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin. Pharmacol. Ther. 2000; 68: 556-567.
- Glue P., Rousier-Panis R., Raffanel С. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis С Hepatology 2000; 32: 647-653.
- Lindsay K., Trepo C., Heintges T. et al. A randomised, doubleblind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
- McHutchison J., Harvey J. Adherence to therapy enhances sustained response in chronic hepatitis С patients receiving PEGinterferon alfa-2b plus ribavirin. J. Hepatol. 2001; 34 (suppl. 1):2.
- Patel K., McHutchinson J. Peginterferon alfa-2b: a new approach to improving response in hepatitis С patients. Expert. Opin. Pharmacother. 2001; 2 (8): 1307-1315.
- Sanchez-Avila J. F., Buti M., Lurie Y. Hepatitis С virus dynamics during induction with high PEG-IFN doses and ribavirin compared with low PEG-IFN doses plus ribavirin in naive patients with chronic hepatitis C, genotype 1. J. Hepatol. 2001; 34 (suppl 1): 5.
Supplementary files
